NCT00005831View on ClinicalTrials.gov

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

August 31, 2004

Conditions
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterSquamous Cell Carcinoma of the BladderStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder
Interventions
BIOLOGICAL

trastuzumab

Given IV

DRUG

paclitaxel

Given IV

DRUG

carboplatin

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

48109

University of Michigan University Hospital, Ann Arbor

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005831 - Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | Biotech Hunter | Biotech Hunter